|

CEL-SCI CORP (CVM)

US1508376076 - Common Stock

2.25  0 (0%)

After market: 2.2 -0.05 (-2.22%)

CEL-SCI CORP

NYSEARCA:CVM (11/30/2023, 5:55:20 PM)

After market: 2.2 -0.05 (-2.22%)

2.25

0 (0%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)08-10 2023-08-10/amc
Earnings (Next)12-26 2023-12-26/bmo
Ins Owners5.06%
Inst Owners11.33%
Market Cap106.33M
Shares47.26M
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts80
IPO12-08 1983-12-08
Stock Screener Links
Screen Image

American Stock Exchange Stock Screener

Find more stocks on American Stock Exchange

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

CVM Daily chart

Company Profile

CEL-SCI Corp. is a biotechnology company, which engages in the research, development, and manufacture of investigational immunotherapy products for the treatment of cancer and infectious diseases. The company is headquartered in Vienna, Virginia. The firm is focused on activating the immune system to fight cancer and infectious diseases. The firm is engaged in research and developing of treatments for cancer and other diseases by using the immune system. Its lead investigational therapy Multikine (Leukocyte Interleukin, Injection) is in a pivotal phase III clinical trial. Its Multikine is an investigational immunotherapy under development for the potential treatment of certain head and neck cancers. The firm is using its Ligand Epitope Antigen Presentation System (LEAPS) technology to develop various new drug candidates, CEL-4000 and CEL-2000, as potential rheumatoid arthritis therapeutic treatments. Its product candidates using its LEAPS technology are CEL-2000, CEL-4000 and DerG-PG275(Cit). The Company’s Multikine is an immunotherapy product candidate comprised of a patented defined mixture of 14 human natural cytokines.

Company Info

CEL-SCI CORP

Suite 802, 8229 Boone Blvd .

Vienna VIRGINIA 22182

P: 17035069460.0

CEO: Geert Kersten

Employees: 0

Website: https://cel-sci.com/

CVM News

News Image10 days ago - CEL-SCI CorporationCEL-SCI Announces Closing of $5 Million Public Offering of Common Stock
News Image14 days ago - ChartmillCurious about what's happening in today's session? Check out the latest stock movements and price changes.

Intrigued by the market activity one hour before the close of the markets on Thursday? Uncover the key winners and losers of today's session in our insightful analysis.

News Image14 days ago - ChartmillWhat's going on in today's session

What's going on in today's session

News Image14 days ago - ChartmillThe market is buzzing with gapping stocks on Thursday. Let's uncover which stocks are experiencing notable gaps during today's session.

There are notable gap-ups and gap-downs in today's session. Let's take a look at which stocks are gapping on Thursday.

News Image14 days ago - Seeking AlphaCEL-SCI announces pricing of $5M offering of common stock (NYSE:CVM)

CEL-SCI announced the pricing of an offering of 2.49M shares of its common stock to a single investor at $2.00 per share, raising $5 million for continued...

News Image14 days ago - CEL-SCI CorporationCEL-SCI Announces Pricing of $5 Million Offering of Common Stock

CVM Twits

Here you can normally see the latest stock twits on CVM, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example